Launxp Biomedical Co (ROCO:6876) Other Current Payables: NT$131.23 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6876 Launxp Biomedical Co Ltd ROCO:6876
11 GF Score
Price NT$14.70
! 4 Warning Signs
View Full Analysis

What is Launxp Biomedical Co Other Current Payables?

Launxp Biomedical Co ROCO:6876 -2.00% 11 Other Current Payables is NT$131.23 Mil as of Dec. 2025. GuruFocus rates ROCO:6876 with a GF Score™ of 11/100. The stock has 4 warning signs investors should review.

Launxp Biomedical Co's Other Current Payables for the quarter that ended in Dec. 2025 was NT$131.23 Mil.

Launxp Biomedical Co's quarterly Other Current Payables increased from Dec. 2024 (NT$9.97 Mil) to Jun. 2025 (NT$264.76 Mil) but then declined from Jun. 2025 (NT$264.76 Mil) to Dec. 2025 (NT$131.23 Mil).

Launxp Biomedical Co's annual Other Current Payables declined from Dec. 2023 (NT$18.07 Mil) to Dec. 2024 (NT$9.97 Mil) but then increased from Dec. 2024 (NT$9.97 Mil) to Dec. 2025 (NT$131.23 Mil).

Launxp Biomedical Co Other Current Payables Related Terms

Launxp Biomedical Co Other Current Payables Historical Data

* Premium members only.

The historical data trend for Launxp Biomedical Co's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Launxp Biomedical Co Other Current Payables Chart

Launxp Biomedical Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial 3.51 5.98 18.07 9.97 131.23

Launxp Biomedical Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 18.07 9.13 9.97 264.76 131.23
ROCO:6876
11GF Score
Launxp Biomedical Co Ltd ROCO:6876
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Launxp Biomedical Co Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of NT$131.23 Mil mean?
Launxp Biomedical Co (ROCO:6876) has a Other Current Payables of NT$131.23 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Launxp Biomedical Co and its competitors.
Is Launxp Biomedical Co's Other Current Payables too high?
Launxp Biomedical Co's current Other Current Payables is NT$131.23 Mil. Overall, Launxp Biomedical Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Launxp Biomedical Co's Other Current Payables compare to VRTX and REGN?
Launxp Biomedical Co's Other Current Payables of NT$131.23 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Launxp Biomedical Co and its competitors. Launxp Biomedical Co's current Other Current Payables is NT$131.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Launxp Biomedical Co stock overvalued right now?
Launxp Biomedical Co (ROCO:6876) has a current Other Current Payables of NT$131.23 Mil. The current Other Current Payables is NT$131.23 Mil. Launxp Biomedical Co's overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Launxp Biomedical Co (ROCO:6876), the current Other Current Payables is NT$131.23 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Launxp Biomedical Co Business Description

Address 10F, No. 51, Section 2, Gongyi Road, Nantun District, Taichung, TWN, 408
Launxp Biomedical Co Ltd is a company that researches, designs and develops Cancer drug rapid screening platform and Early development evaluation and technology licensing of generic drugs for cancer treatment. The company mainly focuses on the screening of development drugs, formulation of development strategies, project management, planning and execution of regulations and clinical trials, etc.
11GF Score

Get the complete analysis for ROCO:6876

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$14.70
Price